EXT Life Sciences is coming toward the end of the tunnel when it comes to commercializing its first product.
The TechTown-based firm is developing a drug that could turn out to be a powerful yet versatile anti-oxidant. The drug, a spin-off of Wayne State University research, works sort of like a smart missile that neutralizes production of harmful oxidants without affecting other parts of the cell.
EXT Life Sciences is in its third round of finance fundraising. It hopes to lock down the rest of the money it needs to finish commercializing its product this year.
"The sooner the better, but it’s hard to find fundraising in this market," says John I. Tesija, secretary treasurer of EXT Life Sciences.
A staff expansion could be in order for the start-up when it lands that money. Right now the firm employs two people on top of the handful of partners and the occasional intern.
Source: John I. Tesija, secretary treasurer of EXT Life Sciences
Writer: Jon Zemke
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.